A US politician just disclosed the purchase of multiple new stocks, including two in biotechnology and research – a sector she oversees in Congress.

Bio-Techne Corporation shares financial results for the first quarter of Fiscal 2026, noting revenue impacts, segment performance, and future outlook.

Bio-Techne Corporation's Board of Directors declares a quarterly dividend of $0.08 per share, effective November 28, 2025, for investors.

Bio-Techne (NASDAQ: TECH) reported first quarter fiscal 2026 results for the period ended September 30, 2025.Key figures: net sales $286.6M (down 1% YoY), GAAP EPS $0.24 versus $0.21, adjusted EPS $0.42 (flat YoY), and adjusted operating margin 29.9%. GAAP operating income rose 19% to $47.7M and GAAP operating margin improved to 16.6% from 13.8%.The company completed the divestiture of Exosome Diagnostics (EPI), cited productivity and cost containment gains, and flagged short- and intermediate-term order timing headwinds in its GMP proteins business tied to customer regulatory progress.

A collaboration between U.S.-based Bio-Techne and Israeli AI specialist Nucleai has, for the first time in a clinical trial, identified spatial immune interactions within tumor tissue as predictors of treatment success in metastatic melanoma. Data from the SECOMBIT trial will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting as one of the top 150 abstracts selected from over 1,200 submissions (Poster #528).

Bio-Techne and Nucleai's collaboration unveils a groundbreaking method for predicting biomarkers in melanoma patients, enhancing treatment personalization.

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne's COMET™ platform and Nucleai's multimodal spatial operating system profiled 42 biopsies, revealing immune...

ScaleReady, along with its partners, has granted Sonoma Biotherapeutics $300,000 to fast-track the development of innovative Treg therapies for autoimmune diseases.

The ProximityScope™ assay, launched by Bio-Techne on Leica's BOND RX platform, enhances spatial protein interaction research, delivering clarity and efficiency.

Bio-Techne (NASDAQ: TECH) launched the ProximityScope™ assay on the Leica Biosystems BOND RX staining platform on October 28, 2025, enabling visualization of functional protein-protein interactions in fixed tissue at subcellular resolution.The assay produces a visual signal only when two proteins are physically close, integrates with ACD's RNAscope Multiomic LS kit for RNA and protein detection on the same section, and automates spatial multiomic workflows via Leica's BOND RX. The workflow will be showcased at SITC, Nov 7-8, 2025 (Booth 603). Bio-Techne reported over $1.2B net sales in fiscal 2025 and about 3,100 employees.

Bio-Techne (TECH) made headlines by announcing an expanded partnership with Oxford Nanopore Technologies. This move extends their collaboration through 2032 and empowers Bio-Techne to broaden its port...

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit

MINNEAPOLIS, Oct. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products,

MINNEAPOLIS, Oct. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products,

MINNEAPOLIS, Oct. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products,